BRAIN Biotech AG has the GF Score of 65, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes BRAIN Biotech AG
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
BRAIN Biotech AG (HAM:BNN) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
BRAIN Biotech AG GF Score Related Terms
HAM:BNN vs LIN, SHW, ECL: GF Score Comparison
For the Specialty Chemicals subindustry, BRAIN Biotech AG's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BRAIN Biotech AG GF Score vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's GF Score distribution charts can be found below:
* The bar in red indicates where BRAIN Biotech AG's GF Score falls into.
BRAIN Biotech AG (HAM:BNN) has a GF Score of 65 as of Jul. 09, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on BRAIN Biotech AG and its competitors. This is near median its historical median of 61.00. Over the past decade, BRAIN Biotech AG's GF Score has ranged from 10.00 to 74.00.
Is BRAIN Biotech AG's GF Score too high?
BRAIN Biotech AG's current GF Score of 65 is near median its 10-year median of 61.00. Over the past 10 years, this metric has ranged from a low of 10.00 to a high of 74.00. Overall, BRAIN Biotech AG has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BRAIN Biotech AG's GF Score compare to LIN and SHW?
BRAIN Biotech AG's GF Score of 65 can be compared against companies in the Chemicals industry. Historically, BRAIN Biotech AG's own GF Score has ranged from 10.00 to 74.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Chemicals company?
A good GF Score depends on the Chemicals industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on BRAIN Biotech AG and its competitors. BRAIN Biotech AG's current GF Score is 65, which is near median its own 10-year median of 61.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRAIN Biotech AG stock overvalued right now?
Based on GuruFocus' analysis, BRAIN Biotech AG (HAM:BNN) is currently considered Fairly Valued. The stock's GF Value™ is €2.48, compared to a current price of €2.71 — trading 9.3% above its estimated fair value. The current GF Score is 65, which is near median its 10-year median of 61.00. BRAIN Biotech AG's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For BRAIN Biotech AG (HAM:BNN), the current GF Score is 65 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRAIN Biotech AG (HAM:BNN) Overvalued in 2026?
Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued.
The current stock price of €2.71 is trading 9.3% above its estimated GF Value™ of €2.48.
GuruFocus considers BRAIN Biotech AG to be Fairly Valued.
Key valuation signals for HAM:BNN:
GF Score: 65 (near median its 10-year median of 61.00)
GF Value™: €2.48 vs. price of €2.71 (9.3% above fair value)
No single metric tells the full story. See the HAM:BNN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
65GF Score
Get the complete analysis for HAM:BNN
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:BNN has been successfully added to your 